Price rise for anti-allergy EpiPen sparks furore
Fivefold price hike of epinephrine injector makes it unaffordable to many US sufferers
Add BT as a preferred sourceWashington
A FIVEFOLD price hike for EpiPen, which allergy sufferers use to counteract life-threatening reactions, has made Mylan the newest drugmaker to come under attack in the United States for profiteering.
Mylan Pharmaceuticals, which holds a near-monopoly position on the epinephrine injectors used by millions against severe allergic attacks, was assailed by two powerful US senators for pumping up the price over six years from US$100 to more than US$500.
TRENDING NOW
When every phone becomes a satellite phone, what happens to Asia’s telcos?
Koh Brothers Eco Engineering faces up to S$57.6 million in potential legal liabilities
Father-and-son duo Raj Kumar and Kishin in exclusive due diligence to buy Scotts Square
Anytime Fitness Asia’s owner said to weigh US$400 million sale
